G6PD抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using G6PD mouse mAb against Hela (1), MCF-7 (2), Jurkat (3) and K562 (4) cell lysate.    

  
  

•  

   

     Western blot analysis using G6PD mouse mAb against  C2C12 cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using G6PD mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of  C6 cells using  G6PD mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of  NIH3T3 cells using  G6PD mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using G6PD mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using G6PD mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit testicles using G6PD mouse mAb with DAB staining.    

  
  

G6PD (glucose-6-phosphate dehydrogenase) antibodies are immunological tools used to detect or study the G6PD enzyme, a critical protein in the pentose phosphate pathway. This enzyme protects cells, particularly red blood cells, from oxidative damage by maintaining reduced glutathione levels. G6PD deficiency, a genetic disorder caused by mutations in the G6PD gene, is the most common human enzyme deficiency, affecting over 400 million people globally. While the condition is primarily linked to hereditary mutations, G6PD antibodies are not typically associated with the deficiency itself. Instead, they serve as research or diagnostic reagents.

In clinical settings, anti-G6PD antibodies are employed in laboratory assays (e.g., Western blot, ELISA) to quantify G6PD protein levels or assess enzyme activity in suspected deficiency cases. Researchers use these antibodies to investigate G6PD's role in oxidative stress, metabolic disorders, and diseases like cancer or neurodegeneration. Notably, autoimmune conditions rarely involve G6PD-targeting autoantibodies, though isolated cases have been reported in atypical hemolytic syndromes. Commercial G6PD antibodies are usually raised in animal models against purified human G6PD protein, enabling species-specific detection. Understanding G6PD biology through antibody-based studies remains vital for exploring therapeutic strategies for deficiency-related complications and broader metabolic dysfunctions.